CN105727249A - 治疗猫、犬关节病症的外用膏剂及其制备方法 - Google Patents
治疗猫、犬关节病症的外用膏剂及其制备方法 Download PDFInfo
- Publication number
- CN105727249A CN105727249A CN201610172401.4A CN201610172401A CN105727249A CN 105727249 A CN105727249 A CN 105727249A CN 201610172401 A CN201610172401 A CN 201610172401A CN 105727249 A CN105727249 A CN 105727249A
- Authority
- CN
- China
- Prior art keywords
- parts
- cruise
- cream
- radix dipsaci
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000282326 Felis catus Species 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000006071 cream Substances 0.000 title abstract description 7
- 241000282472 Canis lupus familiaris Species 0.000 title abstract 2
- 208000012659 Joint disease Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 claims abstract description 58
- 229940079593 drug Drugs 0.000 claims abstract description 23
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 19
- 102000008186 Collagen Human genes 0.000 claims abstract description 19
- 108010035532 Collagen Proteins 0.000 claims abstract description 19
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 18
- 229960001193 diclofenac sodium Drugs 0.000 claims abstract description 18
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims abstract description 18
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 13
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 229920001436 collagen Polymers 0.000 claims abstract 2
- 241001537211 Perna canaliculus Species 0.000 claims description 28
- 229940057995 liquid paraffin Drugs 0.000 claims description 12
- 239000002674 ointment Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 229940099259 vaseline Drugs 0.000 claims description 12
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims 1
- 102000002322 Egg Proteins Human genes 0.000 claims 1
- 108010000912 Egg Proteins Proteins 0.000 claims 1
- 235000014103 egg white Nutrition 0.000 claims 1
- 210000000969 egg white Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 208000002193 Pain Diseases 0.000 abstract description 7
- 210000000988 bone and bone Anatomy 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 210000000845 cartilage Anatomy 0.000 abstract description 2
- 230000003467 diminishing effect Effects 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 208000031295 Animal disease Diseases 0.000 abstract 1
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 241000123589 Dipsacus Species 0.000 abstract 1
- 241001116742 Drynaria Species 0.000 abstract 1
- 241001598107 Imperata Species 0.000 abstract 1
- 241000237536 Mytilus edulis Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 abstract 1
- 235000020638 mussel Nutrition 0.000 abstract 1
- 235000019477 peppermint oil Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 description 10
- 206010003246 arthritis Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010050031 Muscle strain Diseases 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000282465 Canis Species 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000037075 skin appearance Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于兽药领域，尤其涉及治疗猫、犬关节病症的外用膏剂及其制备方法，制备膏剂有效成分的原料重量份组成为白茅根515份、续断2030份、骨碎补2030份、薄荷油13份、冰片15份、D氨基葡萄糖盐酸盐515份、硫酸软骨素515份、胶原蛋白28份、绿唇贻贝28份、双氯芬酸钠28份，本发明配方合理有效，消炎镇痛，改善关节软骨的代谢，降低动物病患处带来的痛楚感，且对动物的肝肾器官无损伤；制备方法简单，将中药组合物加工后做成膏剂，能够提高粘附效果，防止药物脱落，涂抹在关节骨骼处的肌肤外表，直达病位，药效发挥快，使得药物能够充分发挥药效。
Description
技术领域
本发明属于兽药技术领域，尤其涉及治疗猫、犬关节病症的外用膏剂及其制备方法。
背景技术
猫、犬类动物的关节病症主要表现为各类关节炎症、关节疼痛、肌肉扭伤劳损、骨质疏松、骨质发育不良等病状，属于宠物临床治疗的常见病种，这是因为一方面猫、犬的寿命相对较短，五岁之后即步入中老年状态，而在中老年状态中，最容易发生病变的部位即骨骼关节；另一方面是针对体型较大的犬只，由于其小时候生长速度过快，骨骼需要承受较大的自身压力，很容易引发骨骼关节处的病变。
现有技术中的相关治疗药物多采用口服方式，但口服药物发挥药效较慢，而且对动物的肝肾损伤较大。因此猫、犬类动物的关节病症时刻困扰着医生和宠物主人，本领域技术人员亟需研发一种能够有效促进关节和骨骼的快速愈合且副作用较小的药物。
发明内容
本发明的目的是提供一种治疗猫、犬关节病症的外用膏剂及其制备方法，本发明所述外用膏剂直接涂抹在关节骨骼处的肌肤外表，直达病位，疗效快速明显且保护肝肾不受损伤。
为解决上述技术问题，本发明采用的技术方案如下：
设计一种治疗猫、犬关节病症的外用膏剂，以重量份计，其制备原料包括：白茅根5-15份、续断20-30份、骨碎补20-30份、薄荷油1-3份、冰片1-5份、D-氨基葡萄糖盐酸盐5-15份、硫酸软骨素5-15份、胶原蛋白2-8份、绿唇贻贝2-8份、双氯芬酸钠2-8份。
优选的，其制备原料包括：白茅根8-12份、续断23-27份、骨碎补23-27份、薄荷油1-3份、冰片1-5份、D-氨基葡萄糖盐酸盐8-12份、硫酸软骨素8-12份、胶原蛋白3-7份、绿唇贻贝3-7份、双氯芬酸钠3-7份。
优选的：白茅根10份、续断25份、骨碎补25份、薄荷油2份、冰片3份、D-氨基葡萄糖盐酸盐10份、硫酸软骨素10份、胶原蛋白5份、绿唇贻贝5份、双氯芬酸钠5份。
所述宠物用金创膏的制备方法，包括如下步骤：
1）按所述重量份取各原料药，将白茅根、续断、骨碎补、绿唇贻贝混合后制成超微粉，然后与剩余原料药物混合；
2）将凡士林与液体石蜡按体积比2:1混合制成共融物，然后将混合药物与共融物按质量比3:1混合并搅拌均匀即得所需药膏。
各原药成分的药理药效如下：
白茅根：性寒凉，可以祛关节因炎症及疼痛引起的内热；
续断：性微温，味苦、辛；归肝、肾经，用于治疗风湿痹痛、筋伤骨折、跌扑损伤；
骨碎补：性味苦温，归肝肾经，可用于治疗跌打损伤，续筋接骨；
薄荷油、冰片：镇痛消炎，减轻疼痛；
D-氨基葡萄糖盐酸盐：能促进体内粘多糖的合成，提高关节滑液的粘性，改善关节软骨的代谢，对治疗风湿性关节炎症有良好的效果；
硫酸软骨素：与氨基葡萄糖配合使用，具有止痛，促进软骨再生的功效，可以从根本改善关节问题；
胶原蛋白：胶原蛋白是软骨组织中的重要组成成分，用于改善关节软骨的代谢；
绿唇贻贝：富含ω-3脂肪酸，可有效缓解关节炎症状，促进关节的健康，提高舒适感和活动能力；
双氯芬酸钠：缓解类风湿关节炎、骨关节炎等各种慢性关节炎的急性发作期或持续性的关节肿痛症状。
本发明与现有技术相比，具有如下优点：
1）配方合理有效，消炎镇痛，改善关节软骨的代谢，降低动物病患处带来的痛楚感，且对动物的肝肾器官无损伤；
2）制备方法简单，将中药组合物加工后做成膏剂，能够提高粘附效果，防止药物脱落，涂抹在关节骨骼处的肌肤外表，直达病位，药效发挥快，使得药物能够充分发挥药效。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白，以下结合具体实施例，对本发明进行进一步详细说明。应当理解，此处所描述的具体实施例仅仅用以解释本发明，并不用于限定本发明。
实施例1
按下述重量份取相应原料药物：
白茅根10份、续断25份、骨碎补25份、薄荷油2份、冰片3份、D-氨基葡萄糖盐酸盐10份、硫酸软骨素10份、胶原蛋白5份、绿唇贻贝5份、双氯芬酸钠5份。
按所述重量份取各原料药，将白茅根、续断、骨碎补、绿唇贻贝混合后制成超微粉，然后与剩余原料药物混合；将凡士林与液体石蜡按体积比2:1混合制成共融物，然后将混合药物与共融物按质量比3:1混合并搅拌均匀即得所需药膏。
实施例2
按下述重量份取相应原料药物：
白茅根5份、续断20份、骨碎补20份、薄荷油1份、冰片1份、D-氨基葡萄糖盐酸盐5份、硫酸软骨素5份、胶原蛋白2份、绿唇贻贝2份、双氯芬酸钠2份。
按所述重量份取各原料药，将白茅根、续断、骨碎补、绿唇贻贝混合后制成超微粉，然后与剩余原料药物混合；将凡士林与液体石蜡按体积比2:1混合制成共融物，然后将混合药物与共融物按质量比3:1混合并搅拌均匀即得所需药膏。
实施例3
按下述重量份取相应原料药物：
白茅根15份、续断30份、骨碎补30份、薄荷油3份、冰片5份、D-氨基葡萄糖盐酸盐15份、硫酸软骨素15份、胶原蛋白8份、绿唇贻贝8份、双氯芬酸钠8份。
按所述重量份取各原料药，将白茅根、续断、骨碎补、绿唇贻贝混合后制成超微粉，然后与剩余原料药物混合；将凡士林与液体石蜡按体积比2:1混合制成共融物，然后将混合药物与共融物按质量比3:1混合并搅拌均匀即得所需药膏。
实施例4
按下述重量份取相应原料药物：
白茅根8份、续断23份、骨碎补23份、薄荷油1份、冰片1份、D-氨基葡萄糖盐酸盐8份、硫酸软骨素8份、胶原蛋白3份、绿唇贻贝3份、双氯芬酸钠3份。
按所述重量份取各原料药，将白茅根、续断、骨碎补、绿唇贻贝混合后制成超微粉，然后与剩余原料药物混合；将凡士林与液体石蜡按体积比2:1混合制成共融物，然后将混合药物与共融物按质量比3:1混合并搅拌均匀即得所需药膏。
实施例5
按下述重量份取相应原料药物：
白茅根12份、续断27份、骨碎补27份、薄荷油3份、冰片5份、D-氨基葡萄糖盐酸盐12份、硫酸软骨素12份、胶原蛋白7份、绿唇贻贝7份、双氯芬酸钠7份
按所述重量份取各原料药，将白茅根、续断、骨碎补、绿唇贻贝混合后制成超微粉，然后与剩余原料药物混合；将凡士林与液体石蜡按体积比2:1混合制成共融物，然后将混合药物与共融物按质量比3:1混合并搅拌均匀即得所需药膏。
实施例6
按下述重量份取相应原料药物：
白茅根10份、续断28份、骨碎补25份、薄荷油2份、冰片5份、D-氨基葡萄糖盐酸盐15份、硫酸软骨素10份、胶原蛋白8份、绿唇贻贝7份、双氯芬酸钠7份。
按所述重量份取各原料药，将白茅根、续断、骨碎补、绿唇贻贝混合后制成超微粉，然后与剩余原料药物混合；将凡士林与液体石蜡按体积比2:1混合制成共融物，然后将混合药物与共融物按质量比3:1混合并搅拌均匀即得所需药膏。
实施例7
按下述重量份取相应原料药物：
白茅根15份、续断30份、骨碎补30份、薄荷油2份、冰片1份、D-氨基葡萄糖盐酸盐15份、硫酸软骨素15份、胶原蛋白8份、绿唇贻贝5份、双氯芬酸钠2份。
按所述重量份取各原料药，将白茅根、续断、骨碎补、绿唇贻贝混合后制成超微粉，然后与剩余原料药物混合；将凡士林与液体石蜡按体积比2:1混合制成共融物，然后将混合药物与共融物按质量比3:1混合并搅拌均匀即得所需药膏。
实施例8
按下述重量份取相应原料药物：
白茅根8份、续断20份、骨碎补20份、薄荷油2份、冰片3份、D-氨基葡萄糖盐酸盐10份、硫酸软骨素10份、胶原蛋白6份、绿唇贻贝6份、双氯芬酸钠5份。
按所述重量份取各原料药，将白茅根、续断、骨碎补、绿唇贻贝混合后制成超微粉，然后与剩余原料药物混合；将凡士林与液体石蜡按体积比2:1混合制成共融物，然后将混合药物与共融物按质量比3:1混合并搅拌均匀即得所需药膏。
实施例9
按下述重量份取相应原料药物：
白茅根9份、续断23份、骨碎补23份、薄荷油1份、冰片3份、D-氨基葡萄糖盐酸盐12份、硫酸软骨素12份、胶原蛋白8份、绿唇贻贝6份、双氯芬酸钠4份。
按所述重量份取各原料药，将白茅根、续断、骨碎补、绿唇贻贝混合后制成超微粉，然后与剩余原料药物混合；将凡士林与液体石蜡按体积比2:1混合制成共融物，然后将混合药物与共融物按质量比3:1混合并搅拌均匀即得所需药膏。
实施例10
按下述重量份取相应原料药物：
白茅根7份、续断22份、骨碎补23份、薄荷油3份、冰片3份、D-氨基葡萄糖盐酸盐10份、硫酸软骨素10份、胶原蛋白4份、绿唇贻贝5份、双氯芬酸钠6份。
按所述重量份取各原料药，将白茅根、续断、骨碎补、绿唇贻贝混合后制成超微粉，然后与剩余原料药物混合；将凡士林与液体石蜡按体积比2:1混合制成共融物，然后将混合药物与共融物按质量比3:1混合并搅拌均匀即得所需药膏。
进行药物疗效对比试验
试验方法：针对关节炎症、肌肉扭伤劳损两种症状，分别设试验组和对照组，治疗前肢体均具有相同病症，试验组在肢体关节病患处1次/天涂抹实施例1制备所得的外用膏剂，对照组在肢体关节病患处1次/天喂食常规口服药物。具体实验结果见表1-4。
表1 关节炎症试验组治疗效果表
表2 关节炎症对照组治疗效果表
表3 肌肉扭伤劳损试验组治疗效果表
表4 肌肉扭伤劳损对照组治疗效果表
Claims (4)
1.治疗猫、犬关节病症的外用膏剂，其特征在于，以重量份计，其制备原料包括：白茅根5-15份、续断20-30份、骨碎补20-30份、薄荷油1-3份、冰片1-5份、D-氨基葡萄糖盐酸盐5-15份、硫酸软骨素5-15份、胶原蛋白2-8份、绿唇贻贝2-8份、双氯芬酸钠2-8份。
2.如权利要求1所述的外用膏剂，其特征在于，其制备原料包括：白茅根8-12份、续断23-27份、骨碎补23-27份、薄荷油1-3份、冰片1-5份、D-氨基葡萄糖盐酸盐8-12份、硫酸软骨素8-12份、胶原蛋白3-7份、绿唇贻贝3-7份、双氯芬酸钠3-7份。
3.如权利要求1所述的外用膏剂，其特征在于，其制备原料包括：白茅根10份、续断25份、骨碎补25份、薄荷油2份、冰片3份、D-氨基葡萄糖盐酸盐10份、硫酸软骨素10份、胶原蛋白5份、绿唇贻贝5份、双氯芬酸钠5份。
4.权利要求1-3任一所述治疗猫、犬关节病症的外用膏剂的制备方法，其特征在于，包括如下步骤：
1）按所述重量份取各原料药，将白茅根、续断、骨碎补、绿唇贻贝混合后制成超微粉，然后与剩余原料药物混合；
2）将凡士林与液体石蜡按体积比2:1混合制成共融物，然后将混合药物与共融物按质量比3:1混合并搅拌均匀即得所需药膏。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610172401.4A CN105727249A (zh) | 2016-03-24 | 2016-03-24 | 治疗猫、犬关节病症的外用膏剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610172401.4A CN105727249A (zh) | 2016-03-24 | 2016-03-24 | 治疗猫、犬关节病症的外用膏剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105727249A true CN105727249A (zh) | 2016-07-06 |
Family
ID=56251361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610172401.4A Pending CN105727249A (zh) | 2016-03-24 | 2016-03-24 | 治疗猫、犬关节病症的外用膏剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105727249A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1351471A (zh) * | 1999-03-22 | 2002-05-29 | 卡尔坎食品公司 | 保持宠物关节健康和缓解其关节炎症的宠物食品 |
| CN101389633A (zh) * | 2006-02-23 | 2009-03-18 | 诺瓦提斯公司 | 有机化合物 |
| CN104306959A (zh) * | 2014-10-16 | 2015-01-28 | 河北御芝林生物科技有限公司 | 一种治疗骨质疏松的药物组合物及其制备方法 |
-
2016
- 2016-03-24 CN CN201610172401.4A patent/CN105727249A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1351471A (zh) * | 1999-03-22 | 2002-05-29 | 卡尔坎食品公司 | 保持宠物关节健康和缓解其关节炎症的宠物食品 |
| CN101389633A (zh) * | 2006-02-23 | 2009-03-18 | 诺瓦提斯公司 | 有机化合物 |
| CN104306959A (zh) * | 2014-10-16 | 2015-01-28 | 河北御芝林生物科技有限公司 | 一种治疗骨质疏松的药物组合物及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 胡小勤、黄丽萍主编: "《中药学》", 31 January 2014, 西安交通大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Padmanabhan et al. | Animal products in traditional medicine from Attappady hills of Western Ghats. | |
| Jepson | Exotic animal medicine: a quick reference guide | |
| CN100428950C (zh) | 一种防治鸡肾肿病的药物 | |
| CN101293077B (zh) | 一种用于催产黄鳝的中草药组合物 | |
| Madrewar | Therapeutics of veterinary homoeopathy | |
| JP2003155250A (ja) | 関節痛を緩和する目的の健康食品 | |
| CN106234803A (zh) | 用于治疗仔猪白痢的饲料 | |
| CN103006967A (zh) | 一种用于治疗母猪子宫炎的中药组合物 | |
| CN105727249A (zh) | 治疗猫、犬关节病症的外用膏剂及其制备方法 | |
| ES2259933B1 (es) | Procedimiento de obtencion de un extracto rico en saponinas de killay y jaboncillo combinadas con romero, salvia y tomillo, extracto obtenido y su uso en un compuesto medicinal para el tratamiento de vacunos y equinos. | |
| JPH10120579A (ja) | 津液改善用皮膚外用剤 | |
| CN110876796B (zh) | 一种用于治疗痛风急性发作的中药组合物及其制备方法和应用 | |
| Thakur | Therapeutic use of urine in early Indian medicine | |
| CN114010700A (zh) | 一种含有中药有效成分的无创真皮渗透技术透皮吸收剂的制备方法与应用 | |
| CN105050607B (zh) | 用于治疗关节炎和骨关节炎的方法和组合物 | |
| CN105396086A (zh) | 一种含有毛蛋提取物的治疗风湿性关节炎的保健酒 | |
| CN104906132A (zh) | 一种防治羔羊口炎的膏药制剂 | |
| CN104324319A (zh) | 一种促进骨关节健康的保健品 | |
| CN107212156A (zh) | 一种用于畜禽促生长的千目中药制剂及制备方法 | |
| CN106975044A (zh) | 一种治疗结石的药物及其制备方法和应用 | |
| RU2447894C1 (ru) | Ветеринарное гомеопатическое средство для наружного применения при заболеваниях опорно-двигательного аппарата | |
| Beebe | Chinese Herbal Medicine and Prolotherapy for Treatment of Forelimb Angular Deformity in a Juvenile Bactrian Camel. | |
| Hegde | Nanotechnology and Ayurveda: Emerging opportunity for profitable dairy husbandry | |
| CN107773608A (zh) | 一种用于治疗动物腐蹄病的中药复方透皮剂及其制备方法 | |
| CN105288560A (zh) | 一种治疗骨关节疾病的海洋生物霜剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160706 |
|
| RJ01 | Rejection of invention patent application after publication |